The hotel and gambling operator is expecting the NZICC to pull an additional 500,000 annual visitors into its Auckland precinct within the next two years.
The listed cancer diagnostic company must raise $24 million, in a bid to survive.
Biotech giant's shares plunge 21% at market open on the ASX.
The cancer diagnostics company has reined in its cash burn until Medicare reimbursement of its US tests is resumed.
The space company’s quarterly revenue hit US$200m as net loss fell from US$60.6m to US$45m year on year.
Gentrack seeks to calm naysayers, clawing back some losses.
Briscoe Group boss Rod Duke says subleasing existing spaces instead is ‘way less risk, for greater return’.
SkinKandy has nine stores in New Zealand, and the float could fund expansion to other markets.
CEO Gary Miles provides more detail on Tuesday’s profit warning, rebuts ‘chatter’ on performance pay.
Gentrack extended its slump.